The Correlation of MXD3 Expression Level and Prognosis and Immune Infiltration in Patients with Prostate Cancer
Objective To investigate the expression of MAX dimerization protein 3(MXD3)in prostate cancer(PCa)and its correlation with patient prognosis and immune infiltration.Methods RNA sequencing data and clinical information of PCa samples and normal samples were obtained from TCGA database to compare the MXD3 expression levels between tumors and adjacent nor-mal tissues.Kaplan-Meier survival analysis was performed to assess the prognostic value of MXD3 expression levels and the association between MXD3 and clinical features.Gene enrichment analy-sis was performed using GO and KEGG,and the correlation between MXD3 expression and im-mune cell infiltration in prostate cancer was analyzed using the ESTIMATE algorithm.The ex-pression levels of MXD3 mRNA and protein in PCa tissues were verified by qRT-PCR and protein blotting.Results The expression level of MXD3 was significantly higher in prostate cancer than in normal prostate tissues,and its high expression was significantly correlated with poor progno-sis,and the expression level of MXD3 was positively correlated with the clinical stage of the tumor(P<0.05 or P<0.001).GO function and KEGG pathway enrichment analysis showed that MXD3 was closely related to the division and proliferation of prostate cancer cells.The expression of MXD3 was positively correlated with immune cell infiltration levels of regulatory T cells and follicular helper T cells(P<0.001 and P<0.05),whereas it was negatively correlated with mast cells and CD4+T cells(P<0.01 and P<0.001).The mRNA and protein expression of MXD3 was significantly increased in prostate cancer compared with adjacent tissues(P<0.01).Conclusion MXD3,highly expressed in prostate cancer,can be associated with poor prognosis in patients with prostate cancer.MXD3 participates in the division and proliferation of prostate cancer,and is asso-ciated with immune infiltration.MXD3 could serve as a potential prognostic biomarker and im-mune target.